Effect of inhaled ciclesonide versus fluticasone propionate in patients with mild to moderate asthma (18 to 65 y) (BY9010/M1-129)

Study identifier:BY9010/M1-129

ClinicalTrials.gov identifier:NCT00163332

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Comparison of inhaled ciclesonide (160 mcg b.i.d. or 320 mcg b.i.d.) and fluticasone propionate (250 mcg b.i.d. or 500 mcg b.i.d.) in pretreated patients with mild to moderate asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

No

Study drug

Ciclesonide

Sex

All

Actual Enrollment

30

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Mar 2003
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria